← All trials
NCT04751539
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2018
- Primary completion
- Feb 11, 2019
- Completion date
- Feb 11, 2019
- First posted
- Feb 12, 2021
- Last posted
- May 11, 2021
- Enrollment
- 78
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kind Pharmaceuticals LLCLead sponsor
- Kind Pharmaceuticals LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.